Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2016 / Oct / An Enduring Epidemic
Microbiology & Immunology Clinical care Laboratory management Profession Microbiology and Immunology Infectious Disease

An Enduring Epidemic

The aim is to end the global tuberculosis epidemic by 2030 – but if that’s to happen, we need to close the resource gap

By Michael Schubert 10/21/2016 1 min read

Share

“Global actions and investments fall far short of those needed to end the global [tuberculosis] epidemic.”

World news has been full of bacteria lately, most notably in the wake of the United Nations General Assembly’s resolution on antimicrobial resistance. Given the high-profile nature of that meeting and its outcomes, it would be easy to overlook some of the other recent data – such as the World Health Organization’s 2016 Global Tuberculosis Report (1), which highlights a significant gap between the UN’s goal to end the worldwide TB epidemic and the actions currently being taken to achieve it.

The targets involve an 80 percent reduction in the disease’s incidence rate and a 90 percent reduction in deaths by 2030 – but since 2015, when those targets were established, the epidemic has proven to be larger than expected. Multi-drug-resistant TB (MDR-TB), in particular, is causing crisis: only one-fifth of eligible patients are enrolled for treatment, and the treatment success rate is just over 50 percent. The numbers for extensively drug-resistant TB (XDR-TB) are even worse, with only 28 percent of patients successfully treated. That’s not to say there’s been no improvement – quite the opposite. More countries than ever are testing newly diagnosed TB patients for rifampicin resistance, at least 23 have introduced new, shorter treatment regimens for drug-resistant disease (with success rates up to 90 percent), and at least 70 countries have begun to use new antibiotics like bedaquiline and delamanid against MDR- and XDR-TB. It’s a good start – but it’s not enough. The current funding gap for TB care and prevention is nearly US$2 billion and expected to increase, and an additional $1 billion is needed to develop new vaccines, diagnostics and treatments. And the barriers aren’t just monetary; patients need better education and improved access to care. Will the WHO’s report prompt the necessary actions? That remains to be seen…

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. World Health Organization, “Global Tuberculosis Report 2016”. Available at: http://bit.ly/2dmTTDO. Accessed October 16, 2016.

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Event Tracking and Tracing with EMR
Clinical care
Event Tracking and Tracing with EMR

January 7, 2022

1 min read

Can tracking medical events, rather than patients, help us tackle diagnostic error?

2021: A Laboratory Medicine Roundup
Clinical care
2021: A Laboratory Medicine Roundup

January 18, 2022

3 min read

From transgender health care to the power of pathology podcasts, we take a look at our most popular articles of the last year

Not Just a Sample
Clinical care
Not Just a Sample

January 27, 2022

13 min read

Patient–pathologist interactions are vital – and both sides must work together to make the connection

Video: Not Just a Sample
Clinical care
Video: Not Just a Sample

January 28, 2022

1 min read

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.